2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R. Lyon, Julia Grapsa, Teresa López‐Fernández et al.|European Heart Journal|2022Cited by 2.7k
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R. Lyon, Julia Grapsa, Teresa López‐Fernández et al.|European Heart Journal - Cardiovascular Imaging|2022Cited by 486
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular DiseaseHyun Kuk Kim, Young‐Hoon Jeong, Mark Y. Chan et al.|Thrombosis and Haemostasis|2020Cited by 334
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 studyJonathan P. Piccini, Veronika Eder, Valeria Caso et al.|The Lancet|2022Cited by 310
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)Gregory Y H Lip, Robert Scott-Millar, Jean‐Philippe Collet et al.|EP Europace|2017Cited by 137